کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6001858 1182960 2015 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke
ترجمه فارسی عنوان
سندرم متابولیک، فعال سازی پلاکتها و ایجاد حمله ایسکمیک گذرا یا سکته مغزی ترومبوآمبولیک
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی


- TIA is an important predictor of future ischemic events, including stroke.
- Metabolic syndrome and the causal role of atherosclerosis in the development of TIA are discussed.
- We argue that platelets play a crucial role in TIA and that it should form a fundamental part of new therapeutic targets.

Stroke is the second most common cause of mortality in the world today, where transient ischemic attack (TIA) is a period of focal ischemia, the symptoms of which resemble a thromboembolic stroke. Contrary to stroke, TIA symptoms typically last less than one hour and necrosis is absent. Stroke is often preceded by TIA, making it an important predictor of future ischemic events. The causal role of atherosclerosis in the development of TIA is well established, however, research indicates that the atherosclerotic process begins years earlier with the development of metabolic syndrome, which affects approximately 45% of the adult population worldwide. Metabolic syndrome is present if three or more of the following is present: increased waist circumference, increased triglycerides, decreased HDL, increased fasting glucose and hypertension. This syndrome causes systemic inflammation that activates the coagulation system and may cause the formation of pathological thrombi. The role of platelets in stroke has been studied and platelet activation pathways identified. ADP and thromboxane A2 are the most common activators of platelets in normal physiology. Several pharmacological treatments have been employed to prevent the activation of platelets, the most common of which include aspirin and P2Y12-inhibitors. Although treatment is administered strokes and subsequent TIAs are very common in individuals that suffered an initial event. This indicates that research needs to be done in order to elucidate new therapeutic targets, but also to better treat ischemic events to not only decrease the amount of recurring events but also decrease stroke mortality worldwide.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Thrombosis Research - Volume 135, Issue 3, March 2015, Pages 434-442
نویسندگان
, ,